New Peer-Reviewed Clinical Study Demonstrates Accuracy Of Proove Opioid Risk® To Predict Opioid Abuse In A Primary Care Setting

IRVINE, Calif., June 15, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces a new peer-reviewed study demonstrating the accuracy of Proove Opioid Risk® to help primary care physicians predict patients at-risk for opioid abuse.  This study, entitled, "Validation Study of a Predictive Algorithm to Evaluate Opioid Use Disorder in a Primary Care Setting" has been accepted for publication by the journal Health Services Research & Managerial Epidemiology. This study data was presented as part of a presentation by Proove collaborators entitled, "Utilizing Precision Medicine Technologies to Avoid and Treat Prescription Opioid Abuse."  Panelists included Lynn Webster, MD, FACPM, FASAM; Ramsay Farah, MD, MPH, FAAP, FACPM, FASAM, CPE, CMRO; and Katrina Lewis, MD, BSc.

Researchers teamed with Proove® scientists to conduct a multi-center study in 27 primary care clinics involving 1,689 patients. This study demonstrates that Proove Opioid Risk® is a stable predictor of Opioid Use Disorder (OUD) in a primary care setting with 83.2% accuracy. Compared to questionnaires like the Opioid Risk Tool (ORT) or Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) which struggle to accurately identify patients at low risk, Proove Opioid Risk® has a sensitivity ranging from 91.8% to 100% in its low risk range of scores.

Dr. Ashley Brenton, Director of R&D at Proove and lead author states, "The CDC Guidelines targeting primary care physicians are not enough, as the CDC readily admits synthetic opioid deaths have only increased 72% since their publication. Clearly, physicians need better tools.  This study validates that Proove Opioid Risk® is a stable predictor of opioid abuse in primary care, and confirms other published studies showing this profile's high accuracy."

Proove CEO Brian Meshkin explains, "This study adds to the mounting evidence that precision medicine can accurately identify at-risk patients and guide treatment to reduce pain.  It's a false choice to suggest that we must only choose between restricting opioids to reduce abuse and thereby hurting chronic pain patients, or allowing opioids liberally prescribed to control pain and thus expand opioid abuse.  We can reduce pain and opioid abuse at the same time."

About Proove® Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain.  Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals.  Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.  Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients.  Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America.   For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

SOURCE Proove Biosciences, Inc.

Related Links

http://www.proove.com